264 related articles for article (PubMed ID: 22182746)
21. In situ gelling of alginate/pluronic solutions for ophthalmic delivery of pilocarpine.
Lin HR; Sung KC; Vong WJ
Biomacromolecules; 2004; 5(6):2358-65. PubMed ID: 15530052
[TBL] [Abstract][Full Text] [Related]
22. Poly(N-isopropylacrylamide)-chitosan as thermosensitive in situ gel-forming system for ocular drug delivery.
Cao Y; Zhang C; Shen W; Cheng Z; Yu LL; Ping Q
J Control Release; 2007 Jul; 120(3):186-94. PubMed ID: 17582643
[TBL] [Abstract][Full Text] [Related]
23. Comparison of ion-activated in situ gelling systems for ocular drug delivery. Part 2: Precorneal retention and in vivo pharmacodynamic study.
Rupenthal ID; Green CR; Alany RG
Int J Pharm; 2011 Jun; 411(1-2):78-85. PubMed ID: 21453763
[TBL] [Abstract][Full Text] [Related]
24. Effect of deacetylation degree on controlled pilocarpine release from injectable chitosan-g-poly(N-isopropylacrylamide) carriers.
Luo LJ; Huang CC; Chen HC; Lai JY; Matsusaki M
Carbohydr Polym; 2018 Oct; 197():375-384. PubMed ID: 30007625
[TBL] [Abstract][Full Text] [Related]
25. Dendritic Effects of Injectable Biodegradable Thermogels on Pharmacotherapy of Inflammatory Glaucoma-Associated Degradation of Extracellular Matrix.
Nguyen DD; Luo LJ; Lai JY
Adv Healthc Mater; 2019 Dec; 8(24):e1900702. PubMed ID: 31746141
[TBL] [Abstract][Full Text] [Related]
26. Formulation and investigation of pilocarpine hydrochloride niosomal gels for the treatment of glaucoma: intraocular pressure measurement in white albino rabbits.
Jain N; Verma A; Jain N
Drug Deliv; 2020 Dec; 27(1):888-899. PubMed ID: 32551978
[TBL] [Abstract][Full Text] [Related]
27. The pilocarpine Ocusert Delivery System.
Flach A
Trans Pac Coast Otoophthalmol Soc Annu Meet; 1974; 55():179-208. PubMed ID: 4480721
[No Abstract] [Full Text] [Related]
28. Pharmacodynamic effects of pilocarpine eye drop enhanced by decreasing its volume of instillation.
Lal A; Kataria V; Rajpal A; Khanna N
Indian J Physiol Pharmacol; 1995 Jul; 39(3):267-70. PubMed ID: 8550123
[TBL] [Abstract][Full Text] [Related]
29. [Bioactivity and effect of a mixture of pilocarpine and lysine on the pupil and intraocular pressure in rabbits].
Veselovský J; Oláh Z; Veselovská Z; Veselá A
Cesk Slov Oftalmol; 1998 Nov; 54(6):353-61. PubMed ID: 9919787
[TBL] [Abstract][Full Text] [Related]
30. The most commonly used miotic--now longer acting.
Barsam PC
Ann Ophthalmol; 1974 Aug; 6(8):809-14. PubMed ID: 4416369
[No Abstract] [Full Text] [Related]
31. Thermoresponsive, hydrolytically degradable polymer micelles intended for radionuclide delivery.
Hruby M; Konak C; Kucka J; Vetrik M; Filippov SK; Vetvicka D; Mackova H; Karlsson G; Edwards K; Rihova B; Ulbrich K
Macromol Biosci; 2009 Oct; 9(10):1016-27. PubMed ID: 19554646
[TBL] [Abstract][Full Text] [Related]
32. Vinylpyrrolidone-co-(meth)acrylic acid inserts for ocular drug delivery: synthesis and evaluation.
Barbu E; Sarvaiya I; Green KL; Nevell TG; Tsibouklis J
J Biomed Mater Res A; 2005 Sep; 74(4):598-606. PubMed ID: 16021611
[TBL] [Abstract][Full Text] [Related]
33. [An experimental study on corneal collagen shield vehicle for delivery of pilocarpine].
Sun X; Chu R; Chen N
Zhonghua Yan Ke Za Zhi; 1996 Mar; 32(2):143-6. PubMed ID: 9206235
[TBL] [Abstract][Full Text] [Related]
34. Intraocular pressure-lowering effects of latanoprost monotherapy versus latanoprost or pilocarpine in combination with timolol: a randomized, observer-masked multicenter study in patients with open-angle glaucoma. Italian Latanoprost Study Group.
Bucci MG
J Glaucoma; 1999 Feb; 8(1):24-30. PubMed ID: 10084271
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of multiple doses of 4 and 6% timolol, and timolol combined with 2% pilocarpine in clinically normal beagles and beagles with glaucoma.
Gelatt KN; Larocca RD; Gelatt JK; Strubbe DT; MacKay EO
Am J Vet Res; 1995 Oct; 56(10):1325-31. PubMed ID: 8928950
[TBL] [Abstract][Full Text] [Related]
36. [Examination of hypotensive and miotic effects of different pilocarpine solutions (experimental investigations)].
Kondrat'eva TS; Denisova TV; Bunin AAi ; Iakovlev AA
Vestn Oftalmol; 1976; (2):29-31. PubMed ID: 1014180
[No Abstract] [Full Text] [Related]
37. Polymeric pseudolatices bearing pilocarpine for controlled ocular delivery.
Vyas SP; Ramchandraiah S; Jain CP; Jain SK
J Microencapsul; 1992; 9(3):347-55. PubMed ID: 1403485
[TBL] [Abstract][Full Text] [Related]
38. Effect of charge and molecular weight on the functionality of gelatin carriers for corneal endothelial cell therapy.
Lai JY; Lu PL; Chen KH; Tabata Y; Hsiue GH
Biomacromolecules; 2006 Jun; 7(6):1836-44. PubMed ID: 16768405
[TBL] [Abstract][Full Text] [Related]
39. A new transdermal delivery system for pilocarpine in glaucoma treatment.
Dinslage S; Diestelhorst M; Hille T; Otto K
Ger J Ophthalmol; 1996 Sep; 5(5):275-80. PubMed ID: 8911949
[TBL] [Abstract][Full Text] [Related]
40. Comparative effects of pilocarpine in different vehicles on pupil diameter in albino rabbits and squirrel monkeys.
Cheeks L; Green K; Stone RP; Riedhammer T
Curr Eye Res; 1989 Dec; 8(12):1251-8. PubMed ID: 2627795
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
